The company expects total revenues in the full year of 2022 to be in the range of $4.038B-$4.053B. COVID-19 product revenue is expected to be in the range of $1.441B-$1.451B and non-COVID-19 product revenue is expected to be in the range of $2.597B-$2.602B, representing 502% growth on a GAAP basis and 11% growth on a proforma constant currency basis at the midpoint.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QDEL:
- Billionaire David Rubenstein Says Recession Is Likely, but Stays Heavily Invested in These 2 Stocks
- Quidel TriageTrue hsTnl Test approved by Health Canada
- QuidelOrtho, Runda Medical form JV to develop assays for VITROS Platform
- QuidelOrtho management to meet with Craig-Hallum
- QuidelOrtho provides three-year outlook at investor day
